modelEnfuvirtide
Extends from Pharmacolibrary.Drugs.ATC.J.J05AX07.
Information
| name: | Enfuvirtide | |
| ATC code: | J05AX07 | route: | subcutaneous |
| compartments: | 1 | |
| dosage: | 90 | mg |
| volume of distribution: | 5.5 | L |
| clearance: | 1.4 | L/h |
| other parameters in model implementation | ||
Enfuvirtide is a synthetic 36-amino acid peptide and a fusion inhibitor antiretroviral drug used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. It is approved for use in combination with other antiretrovirals for patients experiencing treatment failure or resistance. Enfuvirtide is administered by subcutaneous injection.
Pharmacokinetics
Pharmacokinetic parameters in HIV-1 infected adult patients after subcutaneous injection. Data based on steady state following twice daily 90 mg dosing.
References
Zhang, X, et al., & Patel, I (2007). Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. Journal of clinical pharmacology 47(4) 510–517. DOI:10.1177/0091270006299089 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17389560
Soy, D, et al., & Sheiner, LB (2003). Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clinical pharmacology and therapeutics 74(6) 569–580. DOI:10.1016/j.clpt.2003.09.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14663459
Mould, DR, et al., & Patel, IH (2005). Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clinical pharmacology and therapeutics 77(6) 515–528. DOI:10.1016/j.clpt.2005.02.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15961983
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)